Abstract
There is scant literature available for pediatric prescribers regarding safety and efficacy of monoclonal antibody formulations against coronavirus disease 2019 (COVID-19). Here, we present 2 cases of serious infusion reactions in adolescent patients receiving the monoclonal antibody bebtelovimab and a succinct review of available antiviral medications for pediatric patients with mild or moderate COVID-19.